Mizuho Highlights Pipeline Potential of Amgen's MariTide and Olpasiran

Mizuho analysts have issued a positive assessment of Amgen's (AMGN) drug development pipeline, emphasizing that two candidate drugs, MariTide and Olpasiran, could significantly enhance the company's growth potential. The analysts noted that the clinical success of these drugs will play a critical role in Amgen's long-term valuation. MariTide stands out as a drug developed for obesity treatment, while Olpasiran is a therapeutic candidate designed for cardiovascular diseases. Mizuho stated that these two drugs have the potential to address current market needs and strengthen Amgen's pipeline. The analysts added that the growing markets in obesity and cardiovascular areas present significant opportunities for these drugs. The firm believes that, alongside Amgen's existing drug portfolio, these new candidates could diversify the company's revenue streams and provide a competitive advantage. Mizuho's assessment indicates that Amgen's R&D investments are beginning to yield results. The analysts predict that if clinical trials are successfully completed, these drugs will strengthen the company's market position. This is not investment advice.